BSI Innate Immunity Conference: Inflammasomes, NLRP3, NETosis and What’s Next for Translational Immunology

We recently attended the BSI Innate Immunity Conference in Manchester on behalf of RoukenBio. It was a great opportunity to step back from day-to-day delivery and take stock of where innate immunity research is heading - particularly in inflammasome biology, the cellular mechanisms that drive inflammation, and the growing focus on translational immunology. Across the programme, a clear theme emerged: rigorous mechanistic insights are increasingly being linked to patient heterogeneity, biomarkers, and the next generation of diagnostics and therapeutics. 

A major theme, especially on day one, was how far the inflammasome field has matured and how many talks now feel “translational by design.” Detailed discussions of NLRP3 activation and its downstream consequences - including caspase-1 activation, IL-1β/IL-18 maturation, and gasdermin D-mediated pyroptosis - reinforced how central this pathway is to innate immune sensing and inflammatory disease. Speakers also showcased innovative methods (endogenous protein tagging, advanced microscopy, measurements of cell swelling, and metabolic profiling) that are helping the community answer increasingly complex questions. While not every study was immediately therapeutic in scope, the message was consistent: much of innate immune biology remains underexplored, and strong mechanistic understanding is essential to inform new targets and accelerate advanced therapies where there is unmet need. 

Equally valuable were the examples showing how “basic” innate immunology can explain patient heterogeneity and point toward actionable strategies. Case studies spanning autoinflammatory disease, sepsis, ARDS, and vaccine responsiveness illustrated how subtle differences in inflammasome signalling can have profound clinical consequences. One particularly striking presentation highlighted data suggesting that early inflammasome responsiveness in sepsis may stratify outcomes, with suboptimal NLRP3 activation associated with worse trajectories. This is exactly the kind of observation that can shape future biomarker thinking, influence clinical trial design, and ultimately, guide intervention choices. 

Alongside inflammasome pathways, another key insight was the importance of NET clearance in determining inflammatory outcomes. While NETosis can be an effective antimicrobial response, pathology appears to arise when these extracellular traps are not efficiently resolved. Several talks explored how factors released during NET formation can transiently impair extracellular DNA degradation, creating a requirement for compensatory immune mechanisms to restore balance. When these clearance pathways are insufficient, NETs persist, become more resistant to degradation, and contribute to sustained, tissue-damaging inflammation. Overall, the meeting reinforced the value of viewing NETosis as a dynamic, time-dependent process - encompassing formation, regulation, and resolution - rather than a single static event. That perspective aligns closely with how we think about assay design and generating robust translational data. 

A further direction of travel was methodological. Multiple speakers underscored a shift away from overexpression systems toward endogenous tagging and higher-resolution, more physiological measurements - because the field increasingly needs “truth in context,” not artefacts of model design. For an immunology CRO, these trends matter even when the exact techniques sit outside our routine workflows: understanding the underlying experimental logic helps us better contextualise emerging therapeutic data, and collaborate more effectively with customers when we develop, optimise, and troubleshoot innate immunity assays (including inflammasome and cytokine readouts). 

Although the programme leaned heavily into discovery immunology (in the best possible way), that is precisely why it was so valuable to attend on behalf of RoukenBio. This upstream science is what ultimately seeds the next wave of therapeutic ideas - while also sparking practical thoughts on how we can expand our innate immunology services to support partners working across target discovery, translational biology, and early development.